Christine Brideau

TL;DR: Etoricoxib represents a novel agent that selectively inhibits COX-2 with 106-fold selectivity in human whole blood assays in vitro and with the lowest potency of inhibition ofCOX-1 compared with other reported selective agents.

TL;DR: The development of a COX-2 inhibitor rofecoxib (MK 966, Vioxx) is described, essentially equipotent to indomethacin both in vitro and in vivo but without the ulcerogenic side effect due toCOX-1 inhibition.

TL;DR: Rofecoxib is a novel COX-2 inhibitor with a biochemical and pharmacological profile clearly distinct from that of current nonsteroidal anti-inflammatory drugs and represents a new therapeutic class of anti- inflammatory agents for the treatment of the symptoms of osteoarthritis and rheumatoid arthritis with improved gastrointestinal tolerability.

TL;DR: The authors describe and show numerous real examples from the biologist-friendly Stat Server® HTS application (SHS), a custom-developed software tool built on the commercially available S-PLUS and StatServer statistical analysis and server software that remotely processes HTS data using powerful and sophisticated statistical methodology.

TL;DR: The time‐dependent inhibition by DFU was decreased by co‐incubation with arachidonic acid under non‐turnover conditions, consistent with reversible competitive inhibition at the COX active site.